These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Predictive value of soluble vascular endothelial growth factor receptor 1 for preeclampsia in second-trimester].
    Author: Chen Q, Zhao Y, Zou L, Wang ZH.
    Journal: Zhonghua Fu Chan Ke Za Zhi; 2007 Mar; 42(3):161-4. PubMed ID: 17537299.
    Abstract:
    OBJECTIVE: To evaluate the predictive value of plasma levels of soluble vascular endothelial growth factor receptor 1 (VEGFR-1, also known as sFlt-1) in second-trimester for preeclampsia. METHODS: One hundred and forty-six pregnant women with normal blood pressure previously were prospectively included in the study. Peripheral venous blood samples were obtained between 20 and 26 gestational weeks. Plasma levels of sFlt-1 were measured by an enzyme-linked immunoassay. RESULTS: (1) Among 146 previously normotensive women, 12 developed preeclampsia (preeclampsia group), 134 remained normal pregnant till the end (normal group). (2) The plasma levels of sFlt-1 in preeclampsia group [(4135 +/- 699) ng/L] was significantly higher than that in normal group [(1490 +/- 1033) ng/L] (P<0.01). The increase in sFlt-1 occurred approximately 10 weeks before the diagnosis of preeclampsia. (3) The best cut-off values for preeclampsia of sFlt-1 was 3344 ng/L, the area under the curve was 0.981, the sensitivity, specificity, positive predictive value, and negative predictive value of sFlt-1 in predicting preeclampsia were 100%, 96%, 67%, and 100%, respectively. CONCLUSION: The maternal plasma levels of sFlt-1 in women with preeclampsia are higher than that in normal pregnant women and may be used as an earlier predictor for identification of patients at risk for preeclampsia.
    [Abstract] [Full Text] [Related] [New Search]